Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar:48:105278.
doi: 10.1016/j.nmd.2025.105278. Epub 2025 Jan 27.

Italian survey on evolving SMA care with disease-modifying therapies: a consensus workshop on nutrition, swallowing, respiratory and rehabilitation care

Affiliations

Italian survey on evolving SMA care with disease-modifying therapies: a consensus workshop on nutrition, swallowing, respiratory and rehabilitation care

Stefania Corti et al. Neuromuscul Disord. 2025 Mar.

Abstract

The landscape of spinal muscular atrophy care is evolving with the emergence of disease-modifying therapies and newborn screening programs, leading to new phenotypes and changing patient needs. This necessitates a reevaluation of existing care recommendations to address new challenges and opportunities in spinal muscular atrophy management. To better evaluate how different areas of care have evolved since the advent of disease-modifying therapies, we focused on highlighting areas where existing practices remain valid, those in which changes are needed and supported by evidence, and those in which further research or experience is required. The initiative brought together experts from the Italian spinal muscular atrophy community, initially involving a survey of care practices and a two-day event with workshops on specific topics. The results of the survey and focus groups provide the experts' opinions of the changing aspects of care for key domains: nutrition and bone health, swallowing, respiratory function, and rehabilitation and management of spine deformities. Suggestions were provided, identifying immediate actionable changes and areas requiring further investigation. This framework represents an initial step towards updating care recommendations in the era of novel therapies. It offers a critical view of the evolving care landscape, balancing established practices with emerging evidence and identifying key areas for future research.

Keywords: Clinical care management; Disease-modifying therapies; Multidisciplinary Care; Spinal muscular atrophy (SMA); Treatment Evolution.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: 1. Stefania Corti – Participated in SAB of Roche, Biogen, Novartis and Sarepta. Her work has involved clinical trials and studies related to neuromuscular conditions. 2. Valeria Sansone - Participated in SAB of Roche, Biogen, Novartis and Sarepta. Her work has involved clinical trials and studies related to neuromuscular conditions. 3. Ilaria Bitetti Participated in SAB of Roche and Novartis. Her work has involved clinical trials and studies related to neuromuscular conditions. 4. Noemi Brolatti - Participated in SAB of Roche and Novartis. Her work has involved clinical trials and studies related to neuromuscular conditions. 5. Giulio Gadaleta - Participated in SAB of Roche and Biogen. His work has involved clinical trials and studies related to neuromuscular conditions. 6. Agata Katia Patanella - Participated in SAB of Roche and Biogen. Her work has involved clinical trials and studies related to neuromuscular conditions. 7. Giorgia Coratti - Participated in SAB of Avexis, Biogen, Novartis, Roche and Sarepta. Her work has involved clinical trials and studies related to neuromuscular conditions. 8. Eugenio Mercuri - Participated in SAB of Avexis, Biogen, Novartis, Roche and Sarepta. His work has involved clinical trials and studies related to neuromuscular conditions. Mercuri received sponsorship due to his clinical and academic position, emphasizing novel SMA treatments.